Posted Mar. 19, 2013 at 4:15 p.m.

Premium Lock OxyBio weighs options to move TBI drug through trials

Published: 2013-03-19 16:15:06
Updated: 2013-03-19 16:15:06

Print this blog post
Oxygen Biotherapeutics Oxygen Biotherapeutics

Oxygen Biotherapeutics' (NASDAQ:OXBT) recent securities offering net $1.9 million -- enough to open clinical trial sites in Switzerland and Israel to study traumatic brain injury drug candidate Oxycyte. Beyond must take other financial steps....

Read More
Read More

WRAL Tech Wire any time: Twitter, Facebook

Copyright 2014 WRAL Tech Wire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll